[Behavior of electrolyte- and acid-base balance with special reference to potassium balance during therapy with xipamid (4-chloro-5-sulfa-moyl-2',6',-salicyloxylidide)].
D000136:Acid-Base Equilibrium / Q000187:drug effects*; D001639:Bicarbonates / Q000097:blood; D002712:Chlorides / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004489:Edema, Cardiac / Q000188:drug therapy*; D004912:Erythrocytes / Q000032:analysis; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011188:Potassium / Q000097:blood / Q000652:urine; D012457:Salicylamides / Q000494:pharmacology / Q000627:therapeutic use; D012964:Sodium / Q000097:blood / Q000652:urine; D013449:Sulfonamides; D013997:Time Factors; D014992:Xylenes / Q000032:analysis / Q000627:therapeutic use
D001639:Bicarbonates; D002712:Chlorides; D004232:Diuretics; D012457:Salicylamides; D013449:Sulfonamides; D014992:Xylenes; D012964:Sodium; D011188:Potassium
Verhalten von Elektrolyt- und Säure-Basen-Haushalt unter besonderer Berücksichtigung des Kaliumhaushaltes während der Behandlung mit Xipamid (4-Chlor-5-sulfamoyl-2',6'-salicyloxylidid)